Rafael Bejar, Ph.D.

2001 University of California, San Diego, La Jolla, CA 
"Rafael Bejar"
Mean distance: 13.61 (cluster 29)


Sign in to add mentor
Larry R. Squire grad student 2001 UCSD
 (Genetic manipulations of synaptic plasticity, learning, and memory: Findings from calcium/calmodulin-dependent protein kinase II and K(v)4.2 transgenic mice.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

DeZern AE, Goll JB, Lindsley RC, et al. (2023) Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions. Blood Advances
Huang YJ, Chen JY, Yan M, et al. (2022) RUNX1 deficiency cooperates with SRSF2 mutation to induce multilineage hematopoietic defects characteristic of MDS. Blood Advances
Bernard E, Nannya Y, Hasserjian RP, et al. (2020) Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine
Malcovati L, Stevenson K, Papaemmanuil E, et al. (2020) SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). Blood
Park SJ, Bejar R. (2020) Clonal Hematopoiesis in Cancer. Experimental Hematology
Pine AB, Chokr N, Stahl M, et al. (2020) Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leukemia & Lymphoma. 1-10
Bejar R. (2019) Advances in Personalized Therapeutic Approaches in Myelodysplastic Syndromes. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 1444-1447
Reilly B, Tanaka TN, Diep D, et al. (2019) DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes. Blood Advances. 3: 2845-2858
Stoner SA, Yan M, Liu KTH, et al. (2019) Hippo Kinase Loss Contributes to Del(20q) Hematologic Malignancies through Chronic Innate Immune Activation. Blood
Bell JA, Galaznik A, Pompilus F, et al. (2019) A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Journal of Patient-Reported Outcomes. 3: 35
See more...